Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Seattle Genetics and Abbott sign manufacturing agreement for SGN-30

Feb. 26, 2004

Enrollment scheduled to conclude in pivotal MyVax trial

Feb. 23, 2004

Harvard Group to acquire assets of NexTherapeutics; IND anticipated for NXT-211

Feb. 20, 2004

New phase II study for MT-201 in prostate cancer

Feb. 16, 2004

Transgene updates status of phase II trials of MVA-Muc1-IL2

Feb. 12, 2004

SPA agreement for PRECISE trial with IL13-PE38QQR, program accepted for FDA CMA Pilot 2 program

Feb. 11, 2004

Fourth phase II trial for AMD-3100 underway

Feb. 11, 2004

Phase II results of a G17-DT combination therapy in advanced gastric cancer

Feb. 10, 2004

Abbott to evaluate Raven's monoclonal antibodies in new collaboration

Feb. 9, 2004

Development status of Arius antibodies

Feb. 5, 2004

Popular Stories

Today's news in brief
BioWorld
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...